Haematology Flashcards

1
Q
What is the key cell type involved in GVHD in an allogenic stem cell transplant?
A. B cells
B. NK cells
C. Dendritic cells
D. T cells
E. Macrophage
A

GVHD is a lymphocyte mediated process.

Answer is T cells.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
1
Q

What is the mechanism of Haemachromatosis?

What gene is involved?

A

HFE C282Y gene mutation –> disrupts HFE beta 2M.
TOO MUCH IRON.

UPREGULATES DMT1 TRANSPORTER
–> Increased Fe absorption

ALSO inhibits Hepcidin therefore less blocking of Fe absorption when patient is in Fe overload.

Presentation:
- haemosiderin in liver, pancreas, heart, joints, skin

Mx is venesection.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
2
Q

How does Iron get absorbed into the body?

What is the role of Hepcidin?

A

Fe++ (ferrous) is converted from dietary Fe+++ via Vitamin C + Cyt B, then transported into the duodenal enterocyte cell via the DMT1 TRANSPORTER on apical membrane.

Once inside the enterocyte, it can be stored as Ferritin (converted back to Fe+++ form)

Fe++ is absorbed into the blood via FERRIPORTIN on the basolateral membrane, then converted to the Fe+++ form in order to be BOUND TO TRANSFERRIN (“Ferric bound to Ferrin”)

This “Ferric-Ferrin” complex is then transported to the bone marrow and liver to act on Transferrin receptors (TfR’s) on RBCs for Hb synthesis.

IN FE OVERLOAD, HEPCIDIN INHIBITS FERRIPORTIN.
(“HepcidIN = INhibits FERRIPORTIN = INhibts Fe absorption)
In Fe overload –> Hepcidin from liver –> internalises Ferriportin–> reduces Fe absorption.

In FE DEFICIENCY, Transferrin receptors TfRs get upregulated (as there is increased demand for Fe)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
3
Q

What are the acquired causes of Fe overload and how do you treat it?

A
Thalassaemia
Sideroblastic anaemia
Blood transfusions
Myelodysplasia
Aplastic anaemia
Chronic liver disease
(note Haemochromatosis is genetic, not acquired)

Mx = IRON CHELATORS
Desferasirox po - S/E diarrhoea, renal
Or
Ferriprox PO - S/E Agranulocytosis

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
4
Q

Explain the 4 stages of Fibrin formation / Coagulation.

A
  1. Initiation
  2. Propagation
  3. Termination
  4. Resolution
  5. Initiation
    - vessel injury and exposure of tissue factor (III)
    - interaction with factor 7 (EXTRINSIC pathway)
  6. Propagation
    - propagation of the clotting process by the coagulation cascade, mainly by INTRINSIC amplification:
    factors 12 –> 11 –> 9 –> 8 plus vWF
    - subsequent generation of activated factor Xa
    - formation of Fibrin plug and platelet aggregation
  7. Termination
    - termination of clotting by anti thrombotic control mechanisms
    - downregulates clotting response and contains the thrombus
  8. Resolution
    - removal of the clot by FIBRINOLYSIS
    - PLASMIN (= tPA released by endothelium) breaks down crosslinked Fibrin –> forms fibrin degradation products ie. D-DIMER.
    Hence D-dimer positivity in clots and DIC.

(note D-dimer negative when there is naturally-occurring primary fibrinolysis, eg. In TTP, cancers)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
5
Q

What are the natural anticoagulants present in the bloodstream at all times?

A

tPA
Urokinase
Protein C
Protein S

  • all released by endothelium

–> breaks down fibrin clot

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
6
Q

In Haemophilia A, at what point would you expect spontaneous bleeding, based on the % activity of factor 8?

A

% Activity of factor 8:
> 50% no bleeding.

> 25% bleeding after severe trauma only.

> 5% - No spontaneous bleeds. Only major bleeding with surgery/trauma. Slight bleeding after minor trauma.

< 1% - Spontaneous bleeding into joints and muscles.
Knees > elbows > ankles

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
7
Q

What parts of the coagulation cascade are reflected by PT, APTT, Thrombin time and the reptilase test?

A

PT = “television factors” 2, 7, 9, 10. Also liver disease, Vit K def, warfarin.

APTT = INTRINSIC = 12, 11, 9, 8, vWF. Also circulating inhibitors such as Lupus anticoagulant. Heparin (=anti thrombin III)

BOTH PT and APTT = reflects the final common pathway. ie. Activated factor Xa and downstream ie. Factor 5, prothrombin (2) –> thrombin (2a) , Fibrin (1a) and factor 13 which makes cross-linking/stable fibrin.

Thrombin time = reflects Fibrinogen conversion to FIBRIN.
If TT is normal then it means the problem lies upstream, ie factor 5 or 10, or prothrombin (factor 2)

If ALL 3 affected (APTT, PT, TT) your differentials should be:
A combined factor deficiency
Presence of inhibitors
Factor 10, 2 or 5 deficiency or dysfunction of some sort
Liver disease
DIC!!! = tissue factor dependent

Reptilase test:
- detects reduced fibrinogen ie. Fibrin clots can’t form

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
8
Q

How do you differentiate between a time-dependent inhibitor and a lupus anticoagulant inhibitor on a mixing study?

A

Failure to correct with mixing study (APTT remains prolonged)
= Lupus Anticoagulant

Normal mixing study PLUS prolonged APTT / failure to correct after 2 hours incubation = Time-dependent inhibitor is present (that now had time to work)
= Factor 8 inhibitor

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
9
Q

What is in Prothrombinex?

When do you use this?

A

PROTHROMBIN-X contains:

  • Prothombin (plasma derived) (note Prothrombin/”factor2” –> Thrombin/2a)
  • X (factor 10)
  • factor 9
  • low levels factor 7

= the TELEVISION FACTORS!!

= Localised to PLATELET MEMBRANE surface

Used in WARFARIN REVERSAL ONLY.
Then give Vit K to maintain effect.

(Contraindicated in DIC, AMI, thrombosis, stroke)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
10
Q

What is in Cryoprecipitate?

When do you use this?

A
Cryo contains:
- Fibrinogen
- factor 8 plus VWF (intrinsic pathway)
- factor 13 (important for cross linking of fibrin to form a stable clot)
- Fibronectin (binds fibrin)
= HELPS TO STOP BLEEDS

Useful in DIC emergencies or Fibrinogen deficiency/dysfunction

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
11
Q

When do you use Recombinant factor VIIa?

A

Contains activated Tissue Factor (III) plus 7a.
(Recombinant 7 – think of extrinsic pathway, vessel injury etc)

Use Recomb”INH”ant Factor 7 in patients with INHIBITORS to factors:
eg. In factor 9 def, or in time-dependent inhibitor factor 8.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
13
Q

What is DDAVP and when do you use it?

A

DDAVP is a synthetic analogue of ADH/ Antidiuretic Hormone

  • -> increases vWF and factor 8
  • -> activates platelet aggregation!!!

USED IN:

  • URAEMIA + BLEEDS
  • vWF deficiency (Von Willebrand disease)

(DDAVP - think of APTT –> vWF and 8)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
14
Q

What is the mode of action of Tranexamic acid?

What are the indications for using Tranexamic Acid?

A

(“TRANNIES don’t like PLACID MEN” [plasmin] )

Tranexamic acid BLOCKS PLASMIN and therefore inhibits Fibrinolysis.

Used for:

  • Mucocutaneous bleeds
  • GI Bleeds
  • tumours that secrete Fibrinolysis proteins

(Note - renally excreted)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

Delayed Immune Mediated Transfusion Reactions.

What is the mechanism of GVHD?
How does it present clinically?
What is the prophylaxis and Mx of GVHD?

A

DELAYED reactions = usually days to weeks after transfusion.

There are THREE types of DELAYED Immune Mediated Transfusion Reactions.

  1. Delayed Haemolytic Transfusion Reactions
  2. Transfusion-associated GVHD
  3. Post-transfusion Purpura

In GVHD:

  • The donor’s T lymphocytes reacts with the recipient’s Antigen (donor’s WBC recognises recipients’s antigen as foreign)
  • Highest risk if HLA mismatch.
  • -> usually 2/52 AFTER AlloSCT or transfusion
  • -> may get pancytopaenia
PRESENTATION:
Acute: 
Skin lesions - diffuse macular rash
Fever
Liver - Abdo pain, nausea
GI - diarrhoea
painful gritty eyes

chronic - any organ can be affected

PROPHYLAXIS -
In AlloSCT - CNI (Tac/CsA), may use MTX of MMF as an adjunct

Can be prevented by using IRRADIATED blood products in patients with:

  • NHL or HL
  • Stem cell or BM transplant
  • Donation from family
  • HLA compatible single donor of platelets / granulocytes

MX with STEROIDS.

(ADDIT: MECHANISM OF OTHER DELAYED REACTIONS - less examinable:
Delayed Haemolytic Transfusion Reactions - due to anamnestic Antibody response to Non-ABO red cell antigens

Post-transfusion Purpura - occurs as a result of prior sensitisation to foreign platelet antigens, usually during pregnancy)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
15
Q

What is TRALI?

A

Transfusion Related Acute Lung Injury, occurs 6 hrs after transfusion.

TRALI is one of the 4 Acute Immune-Mediated Transfusion Reactions.

= donor’s antibodies interacts with recipient’s Leukocytes
(“trA-Li” = Antibodies-to-Leukocytes)
–> granulocyte activation in pulmonary vasculature, resulting in increased vascular permeability
–> activation of COMPLEMENT and Cytokine Storm
–> APO, ARDS

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
16
Q

Acute Immune-Mediated Transfusion Reactions.

What is the mechanism behind:

  1. Haemolytic transfusion reactions
  2. Febrile Non-haemolytic transfusion reactions (FNHTR)
A

Immune mediated transfusion reactions are classified into:
- ACUTE (within 24 hrs of transfusion)
Or
- DELAYED (days to weeks after transfusion)

There are FOUR types of Acute transfusion reactions:

  1. Haemolytic transfusion reactions
  2. Febrile Non-Haemolytic Transfusion Reactions (FNHTR)
  3. Allergic transfusion reactions
  4. TRALI

—Acute transfusion reactions are most often the result of clerical/identification error —

MECHANISMS:

  1. Haemolytic transfusion reactions:
    - Usually due to ABO incompatibility
    - Donor’s ANTIGEN interacts with Recipient’s pre-existing antibodies
    - Results in complement activation, leading to intravascular haemolysis and its associated severe acute inflammatory cascade, which may ultimately progress to DIC, shock, and/or acute renal failure.
    - -> Acute Tubular Necrosis
    - -> Fevers, haemolysis, back pain, DAT positive
  2. FNHTR
    - Donor’s LYMPHOCYTES interact with recipient’s antibody
    - immune mediated but multifactorial mechanism
    - self limiting but still need to investigate fevers

ADDIT:
3. Allergic transfusion reactions - (mechanism is self explanatory) Hypersensitivity reactions to allergens in the transfused blood

  1. TRALI - see next flashcard
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
18
Q

What is the purpose of measuring Factor Xa levels?

A

To measure the adequacy of a LMWH.

LOW ANTI-Xa level = Adequate anticoagulation
HIGH ANTI-Xa level = Insufficient anticoagulation.

Antithrombin III agonists such as Clexane & Dalteparin (inhibit activation of factor X –> Xa)
Fondaparinux (a new “pentasaccharide” selective Xa inhibitor but also indirect action via Antithrombin III)
–> all inhibit coagulation via blocking activation of Xa.

If these drugs are present –> inhibits factor Xa.

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

What is the method for warfarin reversal? (eTG)

A

(From eTG)

OVERDOSE OR POISONING:
- single-dose activated CHARCOAL if patient presents within 1 HOUR of the time of gestation

  • if patients not usually taking warfarin, give Vit K (PHYTOMENADIONE) 10-20mg po or IV stat, and if actively bleeding give ProthrombineX PLUS Fresh Frozen Plasma. Monitor INR 6-12 hourly.

FOR OVER-ANTICOAGULATION in someone already on warfarin:
- INR < 5: omit next dose
- INR 5-9: Vit K (Phytomenadione) 1-2mg orally, or 0.5-1mg (half dose) IV.
- INR >9: Vit K 2.5-5mg PO, or 1mg IV if low risk of bleeding.
If high risk of bleeding, give Vit K 1mg and consider Prothrombinex PLUS FFP.

ANY SIGNIFICANT BLEEDING:
Vit K 5-10mg IV
Prothrombinex PLUS FFP

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
19
Q

BLOOD FILMS. Extended matching question.

Match the abnormality with the haematological condition:

  • tear drop RBCs
  • smear cells
  • Auer rods
  • association with Budd chiari syndrome
  • CD5 and CD19
  • pelger cells
  • howell jolly bodies
  • Pencil cells
    • Rouleaux
  • Hypersegmented neutrophils
  • oval macrocytes
  • Blister cells (RBC blisters)
    • Bite cells
  • Elliptocytes/Ovalocytes
    • Cold agglutination (Rouleaux in cold, spherocytes, polychromasia)
  • Heinz bodies
  • target cells
    • Nucleated red blood cells
    • Acanthrocytes
    • fragmented cells
A
  • tear drop RBCs = myelofibrosis
  • smear cells = CLL
  • Auer rods = AML
  • association with Budd chiari syndrome = PRV
  • CD5 and CD19 expression = CLL
  • Pelger cells = “pale girl” cells :) mainly MyeloDYSPLASIA (but also AML/CML)
  • howell jolly bodies = asplenia (functional or splenectomy)
  • Pencil cells = Fe deficiency (“pencil thin” skinny girls are Fe deficient!)
    • Rouleaux = Multiple Myeloma or Waldenstroms (“Mathew McConaughey (MM) wears a ROLEX”)
  • Hypersegmented neutrophils = B12 deficiency
    (note MMA / Methylmalonic acid is SENSITIVE but not specific for B12 def)
  • oval macrocytes = B12 def
  • Blister cells (RBC blisters) = G6PD def
  • Bite cells = (looks like Pacman cells– “Pacman eats 6 Ghosts”) G6PD def ** with Haemolysis! **
  • Elliptocytes/Ovalocytes = SE Asian Ovalocytosis
  • Cold agglutination (Rouleaux in cold, spherocytes, polychromasia) = Paroxysmal Cold Haemoglobinuria (IgG) OR
    Cold Agglutinin Disease (IgM, associated with Lymphoma and Mycoplasma)
  • Heinz bodies = “BEans means Heinz” = BEta Thalassaemia (excess alpha globins)
  • target cells = (any defective globin chain synthesis eg haemoglobinopathies) Thalassaemia or Sickle cell
  • Nucleated RBCS = immature BABY RBCs!! = normal in infants HbF, In adults indicates Thalassaemia
  • Acanthrocytes (spur, thorn or spiculated cells) = splenectomy, cirrhosis, haemolytic anaemia or Thalassaemia
  • fragmented cells = DIC
How well did you know this?
1
Not at all
2
3
4
5
Perfectly
20
Q

Match the mutations with their haematological conditions, and indicate whether they are good/bad prognostic factors:

  • t (9:22)
  • JAK2
  • t (15:17)
  • t (8:21)
A
  • t (9:22) = Bcr Abl (Philadelphia) = classically CML, but also present in Acute leukaemias AML and ALL.
  • JAK2 = Polycythemia Rubra Vera
  • t (15:17) = good prognosis! = APML
  • t (8:21) = good! = AML

(How to remember: 9:22 “minus one” is 8:21
= CML “minus one” maturation step in the myeloid cell line is AML)

How well did you know this?
1
Not at all
2
3
4
5
Perfectly
22
Q

What is the treatment for PRV and ET?

A
  1. ASPIRIN for clot prophylaxis
  2. HYDROXYUREA for splenomegaly
  3. Venesection
23
Q

CML.
What are the diagnostic findings?
What is the management?

A
DIAGNOSIS OF CML: (the CaMeL carried the "B.I.N.S.")
B = Bcr-Abl t(9:22) 
I = Immature myeloid progenitor cells
N = NEUTROPHILIA!!!
S = Splenomegaly

** 70% risk of transformation into AML! **

The SOKOL Index prognosticates how well a patient will respond to therapy (Scoring involves Age, Spleen size, Platelets, Blast percentage)

MANAGEMENT:
Oral TKIs:
- Imatinib / Nilotinib / Dasatinib (confers >90% DFS)
(Allo SCT not used much now)

24
Q

AML.
What are the diagnostic features?
What is the worst prognostic factor?
What is the management for AML?

A

Epidemiology: Median age 67, usually presents in adult population, Males > Females.

DIAGNOSIS OF AML:
Patients usually present with fatigue and pancytopaenia.
(“Acute = we need 13CDs to play this G.A.M.E.!”)
(Cd13, Genes, Auer, Myeloperoxidase, Erythroblasts)

  • Erythroblasts (RBC blasts) >20%
  • Auer rods
  • Myeloperoxidase positive = myeloid lineage
  • CD13 and CD33 Myeloid antigens on flow cytometry
  • t(9:22) Bcr-Abl = bad
  • t(8:21) = good

POOR PROGNOSTIC FACTORS:
(“OLD PEOPLE shouldn’t Flit their Kits in Philadelphia - it’s a BAD look!”)
- Age > 60 is the WORST prognostic factor (treatment makes no difference)
- Bcr-Abl t(9:22)
- FLiT3 mutation –> early Allo BMT
- Kit mutation

(GOOD prognostic factors: t(8:21) and NPMI mutation)

MANAGEMENT OF AML:
1. Cytarabine (Pyrymidine analogue- anti metabolite)
OR
Anthracyclines (RUBICINS)
2. Allo BMT for relapse (Allo = from another person)

24
Q

A patient presents with epistaxis/bleeding, easy bruising, fatigue and pancytopaenia. BM Bx shows blasts with Auer rods. What is the diagnosis and the likely genetic mutation?

A

Diagnosis is APML with DIC.

APML:

  • usually presents with DIC
  • t(15:17) translocation = good prognosis

TREATMENT = ATRA and ARSENIC

  1. All-trans RETINOIC ACID
    - differentiates promyelocytes (myeloblasts) into normal granulocytes
  2. ARSENIC
    - chemo agent (MOA unknown, promotes apoptosis)
    - causes prolonged QT
25
Q

What is the mechanism of Disseminated Intravascular Coagulopathy?

How do you diagnose DIC (4)?

A

DIC = consumption of platelets and coagulation factors when the clotting cascade is activated –> bleeding.
Dysregulation of the clotting cascade –> uncontrolled thrombin generation –> fibrin deposits in microcirculation)

DIC FINDINGS:

  1. Thrombocytopaenia
  2. Hypofibrinogenaemia (due to secondary fibrinolysis)
  3. D-dimer positive (due to secondary fibrinolysis)
  4. Prolonged PT/APTT

MANAGEMENT TO CONTROL BLEEDING:

  • ICU
  • factor replacement - FFP, Cryoprecipitate and/or platelets
27
Q

Patient presents with lymphadenopathy, hepatosplenomegaly, bruising, mouth ulcers, petechiae, menorrhagia and fatigue. FBC shows anaemia, leukocytosis, thrombocytopenia.
What is the likely diagnosis, Invx and Mx?

A

Acute Lymphocytic Leukaemia / ALL.

Symptoms of ALL are nonspecific, but always suspect if patient presents with HIGH WCC, LNopathy and Hepatosplenomegaly.

Occurs in a tri-modal distribution (age 5, 35 and 80)
Blood film will show Leukaemic lymphoBLASTS.
Bone Mx biopsy confirms ALL if blast cells make up greater than 25%
(No Auer rods! )

Common symptoms:
Signs of anaemia - fatigue, pallor, dyspnoea
LNopathy
Hepatosplenomegaly
Epistaxis, menorrhagia
Signs of thrombocytopaenia - petechiae,ecchymoses
Papilloedema
Nuchal rigidity, meningism
FOCAL NEURO SIGNS
Unilateral & painless TESTICULAR enlargement

Lymphoid antigens on flow cytometry:
CD19 & CD20 on B cells
CD 2, 3, 4, 8 on T cells (CD3 sensitive marker for T cells)

CYTOGENETICS:
Bcr-Abl t(9:22)

MANAGEMENT:

  1. TKI upfront in all patients - Imatinib, Dasatinib
  2. Aggressive Induction and Maintenance chemo for 2 years - hyper CVAD (CTX, Vinc, Doxorubicin, Dexamethasone)
  3. Allo BMT if treatment failure
28
Q

How do you CLINICALLY differentiate ALL from AML?

A

Clinically ALL and AML may be indistinguishable.
Patients present with fatigue, bleeding, easy bruising/petechiae.
May have hepatosplenomegaly.

AML - GUM HYPERTROPHY and SKIN mass/infiltration more common.

ALL - lymphadenopathy, CNS and TESTIS involvement more common.

29
Q

How does CLL present and how do you confirm the diagnosis?

A

Epidemiology / Clinical findings-
MOST COMMON haematological malignancy
Accounts for 40% of all leukaemias in age >65.
M>F.

Majority of patients present with lymphadenopathy (87%)
Around half present with splenomegaly.
One quarter asymptomatic.
Elevated WCC on routine FBC.

Associated with AIHA and thrombocytopenia.

DIAGNOSIS:
- CLONAL lymphocytosis –> MOSTLY B Cells (T cell CLL <1% and more aggressive form)
- Smudge/Smear cells on Film
- CD5 and CD19 CO-EXPRESSION!!!
(CD5 is expressed on T cells (mainly) but also some IgM-secreting B cells)
- CLONALITY = lambda or kappa light chains

  • ZAP-70 is a poor prognostic marker
30
Q

What is the treatment for CLL?

A

Depends on staging!!

  • RAI and Binet staging systems
  • ** May progress to DLBCL ** - always watch!!
  • ZAP70 a POOR prognostic marker.

RAI STAGING SYSTEM (0-4)
0 - lymphocytosis
1 - lymphocytosis plus LNopathy
2 - lymphocytosis plus hepato/splenomegaly
3 - lymphocytosis plus anaemia = HIGH risk
4 - lymphocytosis plus thrombocytopaenia = HIGH risk

BINET STAGING SYSTEM
A - < 2 LN
B - > 3 LN
C - Anaemia = HIGH risk

TREATMENT:
- Low/Mod risk (RAI 0-2, BINET A/B) = watchful waiting

  • High risk (RAI 3-4, BINET C)
    Poor performance status:
    –> oral Chlorambucil or Rituximab

Good performance status: (FCR or ALEMTUZUMAB)

  • -> “FCR” IS THE GOLD STANDARD = Fludarabine, Chlorambucil, Rituximab
  • -> OR ALEMTUZUMAB, a mab against CD52 which is present on the surface of mature lymphocytes only.
30
Q

What is the management for Hodgkin’s Lymphoma?

A

Invx: Follicles and fibrosis on histology

Mx:
depends on HANSEN Clever Score >4

  • Early disease: ABVD for 4 days, then involved field radiotherapy
  • Extensive disease: as above, plus BEACOPP.
    +/- Auto SCT.
31
Q

What is the difference between Myelofibrosis and Myelodysplasia?

A

Both Myelofibrosis and MDS present with LOW blood counts
(in contrast to Myelo”proliferative” where there are high counts of mature cells)

MYELOFIBROSIS:
("people in FIBRO houses cause a RUCKUS and make me SAD" = Myelofibrosis = RUXOLITINIB = Tear drops)
- Tear drop RBCs
- LOW blood counts
- Big SPLEEN
- BM Failure
Mx:
- HYDREA for Splenomegaly
- RUXOLITINIB = JAK2 inhibition 
(Used in primary myelofibrosis, post-PRV myelofibrosis, or post-RTA myelofibrosis)
- Supportive
- Allo SCT

MYELODYSPLASIA
(The “pale girl” (pelger) looked “displaced” after LENA stole her “5 quid” = PELGER cells = 5q deletion = LENAlidomide)
- LOW blood counts
- All 3 cell lines affected
- characterised by “PELGER CELLS” –> neutrophil changes –> hence dysplasia
- MDS is a PRE-LEUKAEMIA state –> **watch for transformation into AML!! **
- CHROMOSOME 5q31 DELETION = GOOD = suggests MILDER disease and good response to LENAlidamide
- females better prognosis

Mx:
Allo SCT
G-CSF
*** Lenalidomide if 5q31 deletion!!

33
Q

What are the aggressive and indolent forms of NHL?

What is the treatment of DLBCL?

A

INDOLENT - Follicular, Marginal

AGGRESSIVE - DLBCL, Burkitts

TREATMENT is based on staging and the “international prognosis index” (ECOG 3-4, Age, HIGH LDH, extranodal sites, stage 3-4 = bad prognosis)
–> LIMITED DISEASE: RCHOP and radiotherapy

–> EXTENSIVE DISEASE: RCHOP and AUTO SCT

–> SALVAGE: AUTO SCT

33
Q

What is MGUS?

A

Usually monoclonal IgG in low levels.
MGUS is a pre-malignant state.

There is a 1% per year risk of development into Waldenstroms or Lymphoproliferative disorders.

34
Q

What is Smouldering Myeloma?

A

Malignant cells on BM Bx but patient is asymptomatic - no CRAB.
Mx is to watch carefully.

35
Q

What conditions do you use AUTO SCT?

A

Myeloma
DLBCL
Hodgkins

36
Q

Multiple Myeloma.

How do you make a diagnosis and what markers do you use for prognosis?
What is the treatment?

A

MM is a cancer of Plasma Cells
Produce an abnormal antibody (PARAPROTEIN)
Presents with CRAB (calcium, renal, anaemia, bony lytic lesions)

DIAGNOSIS:
M PROTEIN or M band = high
usually an IgG&raquo_space; IgA&raquo_space; IgM > IgD

Bone Scan is negative as the scan only picks up OsteoBlastic activity, not Osteoclastic.
(“B = B” ie Bone scan = picks up BLASTIC)

PROGNOSIS:
Based on BETA2 MICROGLOBULIN and ALBUMIN level.

TREATMENT:

  1. Oral Melphalan and Steroids
  2. Then IMMUNOMODULATORS- Thalidomide / Lenalidomide
  3. Then PROTEOSOME INHIBITION- BORTEZOMIB in relapsed disease
    * ** or can give Bortezo 1st-line with steroids if there is RENAL involvement!! ***
  4. (SURVIVAL BENEFIT)– AUTO SCT (allows high dose chemo) plus 6 months of Melphalan.

YOUNG —
** DO NOT GIVE A YOUNG PERSON ANY MELPHALAN AS IT RUINS THEIR STEM CELLS –> OPT FOR AUTO SCT ONLY **

ELDERLY —
Supportive treatment for bony lytic lesions:
Radiotherapy and Bisphosphonates

37
Q

What is paroxysmal Cold Haemoglobinuria?

A

A rare AIHA
Acute intravascular haemolysis on exposure to cold

IgG anti-P antibody –> binds complement to RBCs –> autoimmune haemolysis

Blood film shows Cold agglutination

38
Q

What is the typical presentation of a patient with Paroxysmal Noctunal Haemoglobinuria?

What tests would you order to confirm a diagnosis?

A

(How to remember: “I need a “GP I” trust to manage my PNH…I will go on a AEROPlane to “find” this GP!”)

= “GPI” anchored proteins, most sensitive test is to “find/detect” the GPI Cd55 & 59 is AEROLYSIN)
……………………

PNH is an acquired disorder of the RBC membrane, characterised by haemolysis and thrombophilia, due to absence of (GPI) GLYCO-PHOSPHATIDYL-INOSITOL-anchored proteins on the surface of RBCs.

(= “PIG-A” is an enzyme that anchors proteins to the RBC surface –> essential for GPI anchor.
A DEFECTIVE PIG-A is found in PNH)

It is associated with relative or absolute MARROW HYPOPLASIA.

PRESENTATION:

  1. Haemoglobinuria (in 20% - not all patients)
  2. Budd Chiari Syndrome (hepatic vein thrombosis, characterised by RUQ pain)
  3. Thrombosis
  4. May have Hx of Aplastic Anaemia

TESTS:
1. Urine dipstick = Hburia
2. Urine Micro = ** HAEMOSIDERINuria **
3. FBC = anaemia, thrombocytopaenia
4. Haemolytic screen = high Reticulocytes, high LDH and Bilirubin, low Hapto, DAT usually negative & excludes autoimmune haemolytic anaemias
5. Flow Cytometry showing a LOSS OF THE GPI-ANCHORED PROTEINS CD55 and CD59 on the surface of RBCs.
>1% to >3% of anchor-deficienct granulocytes indicates a diagnosis of PNH
6. *** FLUORESCENT AEROLYSIN = most Sensitive and accurate test!! ** detects GPI-anchor. >1% to >3% of anchor-deficient cells indkcates PNH.

Mx: RBC transfusions

40
Q
  1. What is the most common cause of B12 deficiency?
  2. What is the treatment?
  3. What test confirms clinical B12 deficiency?
  4. How do you measure the amount of B12 that is readily available to the tissues?
  5. What are the most specific and sensitive tests for pernicious anaemia?
A
  1. Most common cause is pernicious anaemia.
  2. Hydroxycobalamin is the treatment for B12 deficiency.
  3. MMA or Methylmalonic acid is SENSITIVE (but not specific) for B12 deficiency. MMA binds to B12.
  4. Measure the “active” B12 with “Holo-transcobalamin 2” as B12 is transported in the circulation by the Transcobalamin2 transporter.
  5. Pernicious anaemia:
    Most SPECIFIC test = Intrinsic Factor (SpecIFic)
    Most SENSITIVE test = Gastric Parietal Cell antibody
40
Q

Alpha Thalassaemia.
Describe the 4 different mutations.
What would you find on Hb electrophoresis?

A

THERE ARE 4 ALPHA GENES (2 on each chromosome).

1 gene deletion is asymptomatic.

Alpha thal TRAIT = 2 gene deletion.
- CIS deletion (–/aa) more common in ASIANS
- TRANS deletion (-a/-a) more common in AFRICANS (“TrANS = AfricANS”)
Hb electrophoresis is normal.
Clinically mild anaemia only.

3 gene deletion = HbH (bbbb)
Hb electrophoresis shows LOW HbA, HbA2 and HbF
Presents with severe neonatal jaundice and hepatosplenomegaly.
Ex is splenectomy and lifelong transfusions, avoid antimalarials and sulfa drugs that may exacerbate HbH.

4 gene deletion is incompatible with life = Hb Barts / Hydrops fetalis.
(gggg)

41
Q

Draw the O2 dissociation curve, and what causes right and left shift.

A

RIGHT SHIFT = RELEASES O2 more READILY
(“CADET!! Face RIGHT!”)

C - CO2
A - Acid
D - DPG
E - Exercise
T - Temperature

LEFT Shift is caused by the opposite of the above, plus others (eg carbon monoxide) = Hb hangs on to oxygen

42
Q

Beta Thalassaemia.
Describe the 2 different mutations.
What would you find on Hb electrophoresis?

A

There are 2 Beta genes.

1 gene involvement (deletion or truncation) = Beta Thal TRAIT or Minor

  • (b/b+) chain is truncated, or (b/b0) chain is deleted
  • usually asymptomatic
  • mutation in “Kozac” consensus sequence
  • Trait protects against malaria
  • Blood film: target, hypochromic & microcytic cells
  • Hb electrophoresis: HIGH HbA2, HIGH HbF, LOW HbA

Both genes involved = Beta Thal MAJOR
(b+/b+) or (b+/b0) or (b0/b0) and also get excess alpha chains (aa/aa) –> membrane damage and cell destruction
- PATIENTS DO NOT MAKE ANY HbA
- severe anaemia and ineffective erythropoiesis –> compensatory erythroid hyperplasia in bone marrow –> also may lead to extramedullary haematopoiesis in liver and spleen
- symptoms present after several months of life due to masking by HbF initially
- presents with skeletal abnormality at 6 months of age, chipmunk facies ie frontal and parietal bossing (due to extramedullary haematopoiesis in skull), hepatosplenomegaly

  • Blood film: NUCLEATED RBCs (due to HbF), target, hypochromic, microcytic cells
  • Hb electrophoresis: HIGH HbA2, HIGH HbF, COMPLETED ABSENCE OF HbA.
  • Mx: Frequent transfusions required
    S/E of frequent transfusions is FE OVERLOAD –> requires chelation (desferiox) –> may require splenectomy due to frequent transfusions
43
Q

What drugs can cause a flare of Acute Intermittent Porphyria?

A

Porphyria is an Auto DOM disease reeling in defects of PBGD/ Porphobilinogen deaminase.

  • -> results in porphyria precursors PBG/Porphobilinogen and ALA accumulate in the body
  • -> porphyrins are reddish colour

Most patients are asymptomatic, but symptoms can be triggered by certain drugs or change in nutrition.

Common features- Abdo/back/limb pain, tachycardia, HTN, n+v, later stages – peripheral motor neuropathy.
Acute attacks - PSYCHOSIS, SEIZURES, n+v, Prox mm weakness, painful hyperasthesia

Attacks are precipitated by:

  • ** PHENYTOIN **
  • FASTING / reduced carb intake
  • Valproate
  • Phenobarbitone
  • SULFONYLUREAS
  • Sulphonamide Abx (Bactrim)
  • OESTROGEN/OCP
44
Q

What is the treatment for psychotic attacks of Acute Intermittent Porphyria?

A

Chlorpromazine (phenothiazines) have antiemetic and antipsychotic properties hence is the medication of choice for acute porphyria episodes with psychosis.

Supportive care
Glucose if necessary

Haem Arginate IV available in US/Europe

45
Q

What is the treatment for Hairy Cell Leukaemia?

A

(“Hairy macCHLary drank PURE CHLOR-INE”!)
2 CHLORodeoxyadenosINE!
this is a PURINE ANALOGUE.

Hairy cell leukaemia is a B cell malignancy.
It is HIGHLY RESPONSIVE a to therapy and may be managed successfully for 10 years or more, even though the disease is not curable.

46
Q

What is the treatment for TTP?

A

A medical emergency!
Urgent plasma exchange
Can give FFP while waiting, but AVOID platelets
Immunosuppression

47
Q

What is the pathogenesis of Acquired TTP?

A

Caused by a deficiency of ADAMTS13 which is a metalloprotease that normally cleaves vWF multimers into smaller sizes. In TTP, LOW ADAMTS13 –> results in large vWF multimers to be released in the circulation –> platelet aggregation at sites of shear stress –> lots of thrombi +++.
–> activation and depletion of platelets.

Presents as a pentad (FAT RN):
Fever (uncommon)
Anaemia (common)
Thrombocytopaenia (common)
Renal impairment
Neurological dysfunction
BLood film is microangiopathic
Everything else (apart from Hb and platelets) is normal, ie Ddimer neg, APTT/PT normal, Fibrinogen normal.
48
Q

Which blood group has the lowest factor 8 levels?

A

Group O individuals have LOWER Factor 8 and vWF levels

49
Q

What can cause HIGH Factor 8 levels and why is this important?

A

AB blood type the highest
Infection, inflammation
Age / Postmenopausal

Elevated factor 8 is associated with an increased risk of VTE

  • -> 45x increased rate of recurrent VTEs!!!
  • -> for each 10% increase in Factor 8 level, there is a 17% increased risk of VTE
50
Q

Which patient population can you use NOACs for DVT prophylaxis?

A

Can use Rivaroxaban / Apixaban as DVT prophylaxis in POST-OP patients following elective KNEE or HIP surgery.

51
Q

What is the specific assay to quantify the presence of

  • Dabigatran
  • Rivaroxaban
  • Apixaban
A

Dabigatran: Dilute thrombin clotting time (Haemoclot assay)
Also TT and APTT prolonged.

Riva and Apixaban - Modified anti-Xa assay specific for Riva / Apixaban
PT may be prolonged or normal - not a good indicator

52
Q

What are the findings in Tumour Lysis Syndrome?

A
"PUCK" -
PO4
Uric acid
Calcium ** LOW **
K+ 

Usually found in lymphoproliferative or leukaemic malignancies due to bulky disease and high tumour burden